-
公开(公告)号：US20230295258A1
公开(公告)日：2023-09-21
申请号：US18041392
申请日：2021-08-10
Applicant: KANAPH THERAPEUTICS INC.
Inventor： Donggeon KIM , Soomin RYU , Dahea LEE , Dongsu KIM , Jihoon CHANG , Byoung Chul LEE
CPC classification number: C07K14/5434 , C07K16/40 , A61P35/00 , C12N15/63 , C07K2317/565
Abstract: The present invention provides a bispecific antibody comprising IL-12 or a variant thereof and an antigen binding site that specifically binds to FAP. The bispecific antibody exhibits an anticancer effect by IL-12. In particular, when the anti-FAP antibody is implemented in one antibody, cancer may be efficiently treated by specifically targeting FAP expressed highly in a tumor, and specifically localizing IL-2 to the tumor site. Therefore, the bispecific antibody may be utilized as a pharmaceutical composition for anticancer treatment, and thus has high industrial application potential.
-
公开(公告)号：US20230295327A1
公开(公告)日：2023-09-21
申请号：US18040632
申请日：2021-08-10
Applicant: KANAPH THERAPEUTICS INC.
Inventor： Dahea LEE , Soomin RYU , Donggeon KIM , Jihoon CHANG , Byoung Chul LEE
CPC classification number: C07K16/2887 , C07K14/5434 , A61P35/00 , C12N15/63 , C07K2317/565 , C07K2317/622 , C07K2317/522
Abstract: The present invention provides a bispecific antibody comprising IL-12 or a variant thereof and an antigen binding site that specifically binds to CD20. The bispecific antibody exhibits an anticancer effect by IL-12. In particular, when the anti-CD20 antibody is implemented in one antibody, IL-12 is specifically localized to a tumor site by targeting CD20, which is specifically expressed in a tumor at a high level, thereby efficiently treating cancer. Therefore, the bispecific antibody can be utilized as a pharmaceutical composition for anticancer treatment, and thus has a high potential for industrial application.
-
Search Results
2
records
(took 0.01 seconds)
